Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.73 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.73 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | CDC42 | P60953 | 1/20 | 0.73 |
| ▸ | RAC1 | P63000 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505819 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL29508603 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL505799 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL8754690 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL29403959 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL11015007 | 0.97 | TDP1 (0.73) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL14364989 | 0.91 | TDP1 (0.65) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL12744118 | 0.91 | TDP1 (0.69) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL9551659 | 0.90 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL12744138 | 0.89 | PTGS2 (0.63) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108504618-B | Recombinant bacterium for expressing lipase with R configuration selectivity and application thereof | 华南理工大学 | 2020-08-18 | — | — | CN | claimed |
| CN-102388014-A | Synthesis method of chiral alpha-aryl propionic acid derivative | DSM IP ASSETS BV | 2012-03-21 | — | — | CN | claimed |
| US-5587318-A | FROM RACEMIC MIXTURES OF THE CORRESPONDING ESTER BY ENANTIOSPECIFIC HYDROLYSIS USING LIPASE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-12-24 | — | — | US | claimed |
| EP-0227078-A1 | Process for preparing (S)-alpha-methylarylacetic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1987-07-01 | — | — | EP | claimed |
| EP-0013506-B1 | PLASTICIZER COMPOSITIONS | MONSANTO COMPANY (US) | 1983-07-06 | — | — | EP | claimed |
| US-4001301-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, ANTI-PRURITIC | SYNTEX CORPORATION (PM) | 1977-01-04 | — | — | US | claimed |
| US-3998966-A | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof | SYNTEX CORPORATION (PM) | 1976-12-21 | — | — | US | claimed |
| JP-60081145-A | — | — | None | — | — | JP | disclosed |
| CN-117355527-B | Anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117355527-A | External anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-11369688-B2 | Hybrid telodendrimers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022089614-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | 上海岸阔医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022089612-A1 | USE OF URIDINE DERIVATIVE IN PREPARATION OF MEDICAMENT | 上海岸阔医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| US-4009197-A | 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof | SYNTEX CORPORATION (PM) | 1977-02-22 | — | — | US | disclosed |
| US-4001301-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, ANTI-PRURITIC | SYNTEX CORPORATION (PM) | 1977-01-04 | — | — | US | disclosed |
| US-3998966-A | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof | SYNTEX CORPORATION (PM) | 1976-12-21 | — | — | US | disclosed |
| US-3980699-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (PM) | 1976-09-14 | — | — | US | disclosed |
| US-3978124-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
| US-3978116-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
| US-3958012-A | ANTIINFLAMMATORY, ANALGESIC AND ANTIPYRETIC ACTIVITY | SYNTEX CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369688-B2 | Hybrid telodendrimers | TELO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTT | TDP1 588/4885L3MBTL1 3205/4885PTGS2 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.